WO2008109533A3 - Human antibodies that bind multiple irta family proteins, and uses thereof - Google Patents

Human antibodies that bind multiple irta family proteins, and uses thereof Download PDF

Info

Publication number
WO2008109533A3
WO2008109533A3 PCT/US2008/055677 US2008055677W WO2008109533A3 WO 2008109533 A3 WO2008109533 A3 WO 2008109533A3 US 2008055677 W US2008055677 W US 2008055677W WO 2008109533 A3 WO2008109533 A3 WO 2008109533A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
disclosure
irta
methods
family proteins
Prior art date
Application number
PCT/US2008/055677
Other languages
French (fr)
Other versions
WO2008109533A2 (en
Inventor
Robert Graziano
Haichun Huang
Lan Yang
Kristopher Toy
Heidi N Leblanc
Original Assignee
Medarex Inc
Robert Graziano
Haichun Huang
Lan Yang
Kristopher Toy
Heidi N Leblanc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc, Robert Graziano, Haichun Huang, Lan Yang, Kristopher Toy, Heidi N Leblanc filed Critical Medarex Inc
Publication of WO2008109533A2 publication Critical patent/WO2008109533A2/en
Publication of WO2008109533A3 publication Critical patent/WO2008109533A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present disclosure provides isolated monoclonal antibodies that bind to multiple IRTA family proteins with high affinity, particularly human monoclonal antibodies. Preferred antibodies of the invention specifically bind an IRTA4 protein and at least one other IRTA family protein. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting IRTA proteins, as well as methods for treating various cancers, such as B cell lymphomas, using anti-IRTA antibodies of this disclosure.
PCT/US2008/055677 2007-03-02 2008-03-03 Human antibodies that bind multiple irta family proteins, and uses thereof WO2008109533A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89278907P 2007-03-02 2007-03-02
US60/892,789 2007-03-02

Publications (2)

Publication Number Publication Date
WO2008109533A2 WO2008109533A2 (en) 2008-09-12
WO2008109533A3 true WO2008109533A3 (en) 2008-10-30

Family

ID=39739054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055677 WO2008109533A2 (en) 2007-03-02 2008-03-03 Human antibodies that bind multiple irta family proteins, and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109533A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756988A1 (en) 2009-04-01 2010-10-07 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
AR096687A1 (en) 2013-06-24 2016-01-27 Genentech Inc ANTI-FCRH5 ANTIBODIES
CN110156893B (en) 2013-12-17 2023-03-03 基因泰克公司 anti-CD 3 antibodies and methods of use
AR105026A1 (en) 2015-06-16 2017-08-30 Genentech Inc ANTIBODIES MATURED BY AFFINITY AND HUMANIZED FOR FcRH5 AND METHODS FOR USE
CN110172449A (en) * 2019-06-04 2019-08-27 上海交通大学医学院附属新华医院 A kind of leukaemia cell's excretion body and its preparation method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105149B1 (en) * 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105149B1 (en) * 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma

Also Published As

Publication number Publication date
WO2008109533A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
WO2007067991A3 (en) Human monoclonal antibodies to o8e
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
WO2006076691A8 (en) Irta-2 antibodies and their uses
WO2008070569A3 (en) Human antibodies that bind cd22 and uses thereof
WO2008076560A3 (en) Human monoclonal antibodies to btla and methods of use
WO2005097185A3 (en) Irta-5 antibodies and their uses
WO2007038637A3 (en) Human monoclonal antibodies to cd70
WO2008074004A3 (en) Human antibodies that bind cd70 and uses thereof
MX2010000537A (en) Monoclonal antibodies against glypican-3.
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
WO2008060367A3 (en) Human antibodies that bind cxcr4 and uses thereof
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007002223A3 (en) Cd19 antibodies and their uses
WO2009073533A3 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
WO2005058815A3 (en) Ip-10 antibodies and their uses
EA200801621A1 (en) ANTIBODIES DIRECTED ON HER-3 AND THEIR APPLICATION
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
EP3009454A3 (en) Antibodies specific to cadherin-17
MX2011009220A (en) Fully human antibodies specific to cadm1.
MX2009013824A (en) Antigen binding proteins that bind par-2.
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2008109533A3 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
WO2006116192A3 (en) Irta-1 antibodies and their uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731265

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731265

Country of ref document: EP

Kind code of ref document: A2